What is IPHYF's gross margin?

Innate Pharma (IPHYF) has a gross margin of -198% and a net margin of -344%.

What is IPHYF's P/E ratio?

Track Innate Pharma (IPHYF) P/E ratio, ROE, and valuation metrics over time.

Where can I see IPHYF's full financials?

See Innate Pharma (IPHYF) income statement, cash flow, and balance sheet — quarterly and annual — alongside insider trading activity.

Innate Pharma (IPHYF) Financials — Revenue, Earnings, Cash Flow

Also trades as: IPH.PA (PAR) · $vol 1M · IPHA (NASDAQ) · $vol 0M

$1.51

-0.14 (-8.53%)

Weekly Expected Move ±4.2%

$1 $1 $2 $2 $2

OTC · Healthcare · Biotechnology · Tech Score Sell · Power 46 · $141.7M mcap · 71M float · 0.0002% daily turnover · Short 100% of daily vol

Overview Chart Smart Money Financials Income Statement Cash Flow Balance Sheet Earnings

Analysis Technicals Weather Peers ESG Institutions Dark Pool Short Interest

📊 Key Metrics

TTM

$12M

Revenue

-85.5% YoY

$-93M

Net Income

+3.5% YoY

$-84M

Free Cash Flow

-64.3% YoY

-198.0%

Gross Margin

-335.7%

Op. Margin

-343.8%

Net Margin

💰 Income Flow

How revenue becomes profit

💵 Cash Flow

⚠️ Cash Burn Where cash goes

🏦 Balance Sheet

Assets = Liabilities + Equity

📈 Financial Health

Profitability

ROE1602.3%

ROA-100.3%

ROIC247.8%

Valuation

P/E-2.6

P/B-3.0

EV/EBITDA0.0

Leverage

Debt/Equity-0.50

Current Ratio0.60

Interest Cov.-25.6x

Quality Scores

Piotroski F1/9

Altman Z—

Beneish M16.95